Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

Core Insights - Acumen Pharmaceuticals has completed enrollment in its ALTITUDE-AD Phase 2 trial for sabirnetug (ACU193), targeting early Alzheimer's disease, ahead of schedule and plans to report topline results in late 2026 [1][2][3] Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies targeting soluble amyloid beta oligomers (AβOs) for Alzheimer's disease [6][7] - The company’s investigational product, sabirnetug (ACU193), is a humanized monoclonal antibody that selectively targets toxic soluble AβOs, which are believed to be a significant factor in the neurodegenerative process of Alzheimer's disease [4][6] Clinical Trial Details - The ALTITUDE-AD trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study that enrolled 542 patients with early Alzheimer's disease across the U.S., Canada, the EU, and the UK [3][5] - Participants were randomized to receive either 35mg/kg or 50mg/kg of sabirnetug or a placebo, with the primary endpoint being the change in the Integrated Alzheimer's Disease Rating Scale (iADRS) at 18 months [3][5] - Secondary endpoints include various cognitive and functional assessments, as well as safety measures [3][5] Previous Trial Results - The Phase 1 INTERCEPT-AD trial indicated that sabirnetug was generally well-tolerated with low rates of ARIA-E and showed significant amyloid plaque reduction compared to placebo at higher doses [2][4]